AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |
Back to Blog
Dr yu lu12/28/2023 ![]() Nature Nanotechnology, 14(4):388-397 (*Co-corresponding author). Precise targeting of POLR2A as a therapeutic strategy for human triple negative breast cancer. Xu J, Liu Y, Li Y, Wang H, Stewart S, Van der Jeught K, Agarwal P, Zhang Y, Liu S, Zhao G, Wan J, Lu X*, He X (2019).Van der Jeught K, Sun Y, Fang Y, Zhou Z, Jiang H, Yu T, Yang J, Kamocka MM, So KM, Li Y, Eyvani H, Sandusky GE, Frieden M, Braun H, Beyaert R, He X, Zhang X, Zhang C, Paczesny S, Lu X (2020).ST2 as checkpoint target for colorectal cancer immunotherapy.Journal of Clinical Investigation, 131(1):e140837 (*co-corresponding author). MAL2 drives immune evasion in breast cancer by suppressing tumor antigen presentation. Fang Y, Wang L, Wan C, Sun Y, Van der Jeught K, Zhou Z, Dong T, So KM, Yu T, Li Y, Eyvani H, Colter A, Dong E, Cao S, Wang J, Schneider BP, Sandusky G, Liu Y, Zhang C, Lu X*, Zhang X (2021).Targeted immunotherapy for HER2-low breast cancer with 17p loss (2021) Science Translational Medicine, 13(580):eabc6894. Li Y, Sun Y, Kulke M, Hechler T, Van der Jeught K, Dong T, He B, Miller KD, Radovich M, Schneider BP, Pahl A, Zhang X, Lu X(2021).Journal of Clinical Investigation, 131(10):e146832. Atractylenolide I enhances responsiveness to immune checkpoint blockade therapy by activating tumor antigen presentation. Xu H, Van der Jeught K, Zhou Z, Zhang L, Sun Y, Li Y, Yu T, Wan C, So K, Liu D, Frieden M, Fang Y, Mosley AL, He X, Zhang X, Sandusky GE, Liu Y, Zhang C, Wijeratne AB, Huang C, Ji G, Lu X (2021).An organoid-based screen for epigenetic inhibitors that stimulate antigen presentation and potentiate T-cell-mediated cytotoxicity. Zhou Z, Van der Jeught K, Fang Y, Yu T, Li Y, Ao Z, Liu S, Zhang L, Yang Y, Eyvani H, Cox ML, Wang X, He X, Ji G, Schneider BP, Guo F, Wan G, Zhang X, Lu X (2021).Three of his postdoctoral fellows were NIH K99/R00 awardees and seven of his past trainees are now independent investigators in the US and other nations. Since independent, he has trained a number of postdoctoral fellows, graduate and undergraduate students in his laboratory. Lu has made a number of seminal discoveries that promote translational development of human cancer research. Lu was inducted to the College of Fellows at American Institute for Medical and Biological Engineering in 2019. ![]() He also has a long-standing interest in biomedical engineering. Lu’s research interest spans across the field of cancer research, including human cancer genomics, targeted cancer therapy and cancer immunotherapy with a focus on solid tumors. Lu moved to Indiana University School of Medicine and was named as Vera Bradley Foundation Professor of Breast Cancer Innovation and Strategic Research Initiative Distinguished Investigator.ĭr. In 2010, he moved to the Department of Cancer Biology, University of Texas MD Anderson Cancer Center and was promoted to Associate Professor in 2012. In 2007, he was recruited as a Tenure-track investigator to the Center for Colon Cancer Research at the University of South Carolina. ![]() He did postdoctoral studies at NIAID/NIH (1998-2000) and at Baylor College of Medicine (2000-2003) and then joined the Faculty in Baylor College of Medicine as a Research Assistant Professor. from Shanghai Institute of Biochemistry, Chinese Academy of Sciences in 1998 (Biochemistry). ![]()
0 Comments
Read More
Leave a Reply. |